Form 4: Relay Therapeutics Director Granted Stock Options

Relay Therapeutics Director Lonnel Coats was granted 207,931 stock options with an exercise price of $6.86, vesting over 36 months.

Summary

• Lonnel Coats, a Director of Relay Therapeutics, Inc. (RLAY), was granted stock options.
• The transaction date for the grant was November 4, 2025.
• The grant consists of 207,931 stock options, each representing a right to buy one share of common stock.
• The exercise price for these stock options is $6.86 per share.
• The options will vest in thirty-six equal monthly installments, commencing after November 4, 2025, contingent on Mr. Coats' continued service with the Issuer.
• The expiration date for these stock options is November 3, 2035.
• Following this transaction, Mr. Coats beneficially owns 207,931 derivative securities directly.

Sentiment

Score: 7

Explanation: The grant of stock options to a director is a positive event for corporate governance and alignment of interests, but it is a routine compensation matter and not a significant operational or financial announcement that would dramatically alter the company's outlook.

Positives

• The grant of stock options aligns the interests of Director Lonnel Coats with those of shareholders, incentivizing long-term performance.
• The options have a 10-year expiration date, providing a long-term incentive horizon.

Future Outlook

The stock options are subject to a 36-month vesting schedule, contingent on the reporting person's continued service, indicating an expectation of long-term engagement.

Industry Context

The grant of stock options to directors is a common practice in the biotechnology and pharmaceutical industries, serving as a key component of executive and director compensation packages to attract and retain talent and align their interests with long-term shareholder value.

Stakeholder Impact

• Shareholders: The grant aligns the director's financial interests with long-term shareholder value creation, as the options gain value if the stock price increases above the exercise price.

Next Steps

• Lonnel Coats' continued service with Relay Therapeutics, Inc. is required for the stock options to vest over the 36-month period.

Key Dates

Keywords

Relay Therapeutics, RLAY, Stock Option, Director Compensation, Insider Transaction, Equity Grant, Lonnel Coats